본문 바로가기

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES22(21) · #11659 · 2021
피인용
Web of Science 39Scopus 41
FWCI (Scopus)
0.66
JCR IF
JCR 2020 5.924
ISSN
1661-6596

저자

  1. Mongre, Raj Kumar제1저자Sookmyung Womens Univ, Mol Canc Biol Lab, Cellular Heterogene Res Ctr, Dept Biosyst, Hyochangwon Gil 52, Seoul 04310, South Korea
  2. Mishra, Chandra BhushanBaylor Coll Med, Dept Pharmacol & Chem Biol, Baylor Plaza, Houston, TX 77030 USA
  3. 아르빈드 쿠마르 수클라Pusan Natl Univ, Sch Biomed Convergence Engn, Yangsan 50612, Gyeongsangnam D, South Korea
  4. Prakash, AmreshAmity Univ Haryana, Amity Inst Integrat Sci & Hlth AIISH, Gurgaon 122413, India
  5. Jung, SamilSookmyung Womens Univ, Mol Canc Biol Lab, Cellular Heterogene Res Ctr, Dept Biosyst, Hyochangwon Gil 52, Seoul 04310, South Korea
  6. Ashraf-Uz-Zaman, MdBaylor Coll Med, Dept Pharmacol & Chem Biol, Baylor Plaza, Houston, TX 77030 USA
  7. Lee, Myeong-Sok교신저자Sookmyung Womens Univ, Mol Canc Biol Lab, Cellular Heterogene Res Ctr, Dept Biosyst, Hyochangwon Gil 52, Seoul 04310, South Korea

초록

GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progression. Receptor tyrosine kinases (RTKs) are crucial intermediaries of the several cellular pathways and carcinogenesis that directly affect the prognosis and survival of higher tumor grade patients. Tyrosine kinase inhibitors (TKIs) are efficacious drugs for targeted therapy of various cancers. Therefore, RTKs have become a promising therapeutic target to cure cancer. A recent report shows that TKIs are vital mediators of signal transduction and cancer cell proliferation, angiogenesis, and apoptosis. In this review, we discuss the structure and function of RTKs to explore their prime role in cancer therapy. Various TKIs have been developed to date that contribute a lot to treating several types of cancer. These TKI based anticancer drug molecules are also discussed in detail, incorporating their therapeutic efficacy, mechanism of action, and side effects. Additionally, this article focuses on TKIs which are running in the clinical trial and pre-clinical studies. Further, to gain insight into the pathophysiological mechanism of TKIs, we also reviewed the impact of RTK resistance on TKI clinical drugs along with their mechanistic acquired resistance in different cancer types.

키워드

receptor tyrosine kinasesdrug resistancetargeted therapycancermutationclinical trialsGROWTH-FACTOR RECEPTORCARBONIC-ANHYDRASE INHIBITORSSMALL-MOLECULE INHIBITORSHUMAN BREAST-CANCERPHASE-II TRIALPIK3CA MUTATIONSIN-VITROACQUIRED-RESISTANCEERBB RECEPTORSDRUG DESIGN

식별자

Scopus EID
2-s2.0-85117937976
WoS UID
000720252400001